Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
Designed to resemble naturally occurring nucleotides and nucleic acids in the body, our SMNH compounds cause no observed non-specific immune response and target a broad range of disease, including viral diseases and cancers.
#oncology$SBPH: https://bit.ly/2QuXgN1 pic.twitter.com/xz0QaAaWmT
-
Citing our two clinical programs, multiple data readouts, high quality partners and a cash runway beyond 2021,
@InvestWatchBlog notes that Spring Bank could be undervalued. Read more.$SBPH: https://bit.ly/2KAKRTP FLS Disclaimer: https://bit.ly/36HTrsH pic.twitter.com/ZvQjWU2B4G
-
Inarigivir selectively activates within cells infected with
#HBV, inhibiting viral replication and causing the induction of intracellular interferon signaling pathways for antiviral defense. Learn more about this mechanism here$SBPH: https://bit.ly/35fjFlG pic.twitter.com/CWpIidYXBb
-
Among our pipeline of compounds, we plan to focus most on the inarigivir compound for
#HBV treatment and SB 11285 for#oncology applications. See our full pipeline here.$SBPH: https://bit.ly/2OnoHWq pic.twitter.com/Nx6bn7VmMi
-
We design our proprietary SMNH compounds to bind specifically to their intended proteins, producing high therapeutic benefit over current therapies. We are committed to the highest standards of scientific excellence and integrity
$SBPH: https://bit.ly/2OuUXXQ pic.twitter.com/sIxS3N9VUk
-
STimulator of INterferon Genes, or STING, is a protein that can activate the body’s innate immune system. SB 11285 is an
#immunotherapy agent that activates the STING pathway currently being developed for the treatment of some cancers.$SBPH: https://bit.ly/2OoHTD7 pic.twitter.com/xXnvWxvBsx
-
We released results from the first cohort of the clinical trial examining the co-administration of the low dose of inarigivir 50mg and the nucleoside analog, Vemlidy®.
$SBPH. Learn more about this trial here from@biospace: https://bit.ly/2OwewPc pic.twitter.com/FcpDg9HXBh
-
Novel Small Molecule Drug Discovery Platform Harnesses Immune System to Defeat Cancers, Viral Infections & Inflammatory Diseases. Read the article from Dr. Kris Iyer in Drug Development & Delivery
@dddmag (FLS Disclaimer: https://bit.ly/2rudoEo ): https://bit.ly/36iimCT pic.twitter.com/fwaCVwewVN
-
Designed to resemble naturally occurring nucleotides and nucleic acids in the body, our SMNH compounds are relatively easy to manufacture and include no observed non-specific immune response
$SBPH : https://bit.ly/32OqNVl pic.twitter.com/piBC3jMoLf
-
We are a clinical-stage
#biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid platform. Want more investment-relevant info? Check here$SBPH: https://bit.ly/33V2wwW pic.twitter.com/PbgdO0xZpW
-
Learn all about our development pipelines in our three main therapeutic areas:
#HBV,#oncology, and inflammatory diseases$SBPH: https://bit.ly/2onRqS4 pic.twitter.com/dNtQplSI4A
-
At Spring Bank, we are committed to the highest standards of scientific excellence and integrity for the benefit of patients and the medical community. Learn more about our mission
$SBPH: https://bit.ly/3672DY8 pic.twitter.com/uKTzzOFaMo
-
Our small molecule nucleic acid hybrid compounds act directly on target proteins, and have the potential to be used as part of combinatorial treatments, for example in
#HBV with other antivirals$SBPH: https://bit.ly/32OqNVl pic.twitter.com/whGckrx6JN
-
Since inception, we have sought to apply our small molecule nucleic acid hybrid chemistry platform toward the discovery and development of novel drugs. The work has culminated in inarigivir, which is now being studied in Phase 2 clinical trials
$SBPH: https://bit.ly/341IbG5 pic.twitter.com/WSou9NjdUO
-
Want to dive deep into the science and documentation behind our technology? Take a look at our publications
$SBPH: https://bit.ly/2PfWLpw pic.twitter.com/q7udMO3XaJ
-
STimulator of INterferon Genes, or STING, is a protein that has the power to activate the body’s innate immune system. SB 11285 is a potent immunotherapeutic agent that activates the STING pathway. Read more about it here.
#oncology$SBPH: https://bit.ly/32NmIkb pic.twitter.com/XOYORLL6n3
-
We are focusing the development of our two most advanced product candidates, inarigivir and SB 11285, on the treatment of
#HBV and various cancers respectively$SBPH: https://bit.ly/2onRqS4 pic.twitter.com/YciDdxZz9j
-
Did you know that attaining a functional cure for chronic
#HBV will likely require modulation of the immune system? Our product candidate inarigivir is being developed with this in mind. Learn more about it$SBPH: https://bit.ly/2BJMqu8 pic.twitter.com/wsohUWv7E7
-
At Spring Bank, we always have confidence in our Board of Directors, given that it is made up of a number of highly accomplished and experienced individuals who each bring their own expertise to the table. Get to know our Board here
$SBPH: https://bit.ly/2JmFlnq pic.twitter.com/g5dkAAItlX
-
Our SMNH compounds target a broad range of diseases, including
#viral and oncological diseases#oncology, and our SMNH technology limits the likelihood of drug-drug interactions$SBPH: https://bit.ly/2BJMqu8 pic.twitter.com/YX49NRPTC0
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.